NTLA

SEC source: 0000950170-24-001204 · ownership.xml · nonDerivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively.

SEC source: 0000950170-24-001210 · ownership.xml · derivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,500

Underlying: Common Stock · 3,500 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0000950170-24-001210 · ownership.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,734

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively.

SEC source: 0000950170-24-001197 · ownership.xml · derivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,850

Underlying: Common Stock · 7,848 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0000950170-24-001197 · ownership.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 865,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0000950170-24-001173 · ownership.xml · derivative · entry 2

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,064

Underlying: Common Stock · 3,062 shares

Expires 2031-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

SEC source: 0000950170-24-001173 · ownership.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001209191-23-054163 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,996

F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023.

SEC source: 0001209191-23-044257 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,261

F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023.

SEC source: 0001209191-23-041951 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,526

F1 · kind: The reported sale of 1,867 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 6, 2023 at each separate price.

SEC source: 0001209191-23-041495 · doc4.xml · nonDerivative · entry 1

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,146

F1 · kind: Sale of 360 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.52, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price.

SEC source: 0001209191-23-039148 · doc4.xml · derivative · entry 3

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,750

Underlying: Common Stock · 5,000 shares

Expires 2030-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 64,062 shares as of June 20, 2023.

SEC source: 0001209191-23-039148 · doc4.xml · nonDerivative · entry 2

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,146

F1 · kind: The reported sale of 5,000 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

SEC source: 0001209191-23-039148 · doc4.xml · nonDerivative · entry 1

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,146

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-037889 · doc4.xml · derivative · entry 2

GOODMAN JESSE · CIK 0001756929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037889 · doc4.xml · nonDerivative · entry 1

GOODMAN JESSE · CIK 0001756929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,716

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037910 · doc4.xml · derivative · entry 2

CHASE WILLIAM J · CIK 0001563572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,447

Underlying: Common Stock · 2,447 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 2,447 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037910 · doc4.xml · nonDerivative · entry 1

CHASE WILLIAM J · CIK 0001563572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,956

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037898 · doc4.xml · derivative · entry 2

Verwiel Frank · CIK 0001545794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037898 · doc4.xml · nonDerivative · entry 1

Verwiel Frank · CIK 0001545794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,716

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037892 · doc4.xml · derivative · entry 2

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037892 · doc4.xml · nonDerivative · entry 1

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,146

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037879 · doc4.xml · derivative · entry 2

Crowley John F · CIK 0001400973 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037879 · doc4.xml · nonDerivative · entry 1

Crowley John F · CIK 0001400973 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,716

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037873 · doc4.xml · derivative · entry 2

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037873 · doc4.xml · nonDerivative · entry 1

Cohen Fred E · CIK 0001339358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,716

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-037860 · doc4.xml · derivative · entry 2

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,473

Underlying: Common Stock · 6,473 shares

Expires 2033-06-13

F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0001209191-23-037860 · doc4.xml · nonDerivative · entry 1

Bhanji Muna · CIK 0001846905 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,393

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0000899243-23-011381 · doc4.xml · derivative · entry 2

CHASE WILLIAM J · CIK 0001563572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,931

Underlying: Common Stock · 14,931 shares

Expires 2033-04-13

F2 · derivative.exercise_date: This option was granted on April 14, 2023 with respect to 14,931 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 14, 2024 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.

SEC source: 0000899243-23-011381 · doc4.xml · nonDerivative · entry 1

CHASE WILLIAM J · CIK 0001563572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,283

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015722 · doc4.xml · nonDerivative · entry 3

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,279

F2 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on March 1, 2023.

SEC source: 0001209191-23-015753 · doc4.xml · derivative · entry 2

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,342

Underlying: Common Stock · 43,342 shares

Expires 2033-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015753 · doc4.xml · nonDerivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,361

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015742 · doc4.xml · derivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,302

Underlying: Common Stock · 42,302 shares

Expires 2033-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015742 · doc4.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,567

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015817 · doc4.xml · derivative · entry 2

Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,287

Underlying: Common Stock · 33,287 shares

Expires 2033-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015817 · doc4.xml · nonDerivative · entry 1

Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,864

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015776 · doc4.xml · derivative · entry 2

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,834

Underlying: Common Stock · 38,834 shares

Expires 2033-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015776 · doc4.xml · nonDerivative · entry 1

Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,888

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015764 · doc4.xml · derivative · entry 3

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,631

Underlying: Common Stock · 128,631 shares

Expires 2033-02-28

F3 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015764 · doc4.xml · nonDerivative · entry 1

LEONARD JOHN M · CIK 0001563584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 857,861

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015732 · doc4.xml · derivative · entry 3

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,674

Underlying: Common Stock · 34,674 shares

Expires 2033-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015732 · doc4.xml · nonDerivative · entry 2

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,146

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015732 · doc4.xml · nonDerivative · entry 1

Clark Eliana · CIK 0001914448 · EVP, Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,012

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015722 · doc4.xml · derivative · entry 4

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,674

Underlying: Common Stock · 34,674 shares

Expires 2033-02-28

F3 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001209191-23-015722 · doc4.xml · nonDerivative · entry 2

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,367

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-015722 · doc4.xml · nonDerivative · entry 1

BASTA JAMES · CIK 0001792726 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,098

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

SEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 3

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,629

F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.

SEC source: 0001209191-23-002433 · doc4.xml · nonDerivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,318

F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.

SEC source: 0001209191-23-002417 · doc4.xml · nonDerivative · entry 1

Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,687

F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.